October 28, 2014 / 10:19 PM / 3 years ago

BUZZ-Gilead Sciences Inc: Sovaldi sales slip

** U.S. drugmaker's shares down about 4 pct at $110.70 in extended trading

** Sales of $84,000 hepatitis C drug Sovaldi dipped as doctors and patients awaited a recently approved combination pill

** Q3 Sovaldi sales $2.8 billion, below the average Wall Street estimate of $2.97 billion, according to Deutsche Bank

** Up to Monday's close, Gilead shares had gained about 51 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below